Abstract 2925
Background
Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a class of antitumor agents that exert their cytotoxic effects by inhibiting PARP activity. PARPis are also capable of trapping PARP proteins complexes on damaged DNA, further augmenting cell death. Pamiparib is a selective PARP1/2 inhibitor with potent PARP trapping ability that can cross the blood-brain barrier and has demonstrated antitumor activity in both in vitro and in vivo nonclinical tumor models harboring BRCA gene mutations (BRCAmut) and other homologous recombination deficiencies. In Phase 1 studies (NCT02361723; NCT03333915), single-agent pamiparib was generally well tolerated and showed antitumor activity, notably in patients with high-grade non-mucinous ovarian cancer (HGOC). Antitumor activity was observed in patients with BRCA mutant and BRCA wild type ovarian cancers, whose tumors were either sensitive or had platinum-resistant disease. Data from these Phase 1 studies support the recommended Phase 2 pamiparib monotherapy dose of 60 mg PO BID.
Trial design
In this ongoing study of pamiparib in China (NCT03333915), patients with HGOC harboring germline BRCAmut who have received ≥2 prior lines of therapy are being enrolled in the Phase 2 part of the study. Patients with either platinum-sensitive (progression occurring ≥6 months after last dose of platinum) or platinum-resistant (progression occurring <6 months after last dose of platinum) HGOC are eligible. Germline BRCAmut status is identified or confirmed by central testing before enrollment. Approximately 100 patients with HGOC (platinum-sensitive, n = 80; platinum-resistant, n = 20) will receive pamiparib 60 mg PO BID until disease progression. The primary objective is to assess overall response rate according to RECIST v1.1; secondary objectives include assessment of pamiparib’s safety, tolerability, and pharmacokinetic profile. Evaluation of antitumor activity will include an estimation of overall and progression-free survival, as well as duration of clinical response.
Clinical trial identification
NCT03333915.
Legal entity responsible for the study
Beigene, Ltd.
Funding
Beigene, Ltd.
Editorial Acknowledgement
Medical writing and editorial support was provided by Regina Switzer, PhD (SuccinctChoice Medical Communications, Chicago, IL).
Disclosure
T. Gu, K. Zhang, J. Liang, S. Mu, R. Ge, H. Yang, V. Huang, R. Brachmann, L. Wang, M. Li: Employee: BeiGene. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract